Translational Science Expected to Play a Growing Role in Creating New Drugs, According to Tufts Center for the Study of Drug Development
27 janv. 2011 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 27, 2011) - To produce drug candidates at the pace needed to remain competitive, pharmaceutical and biotech companies increasingly are using translational science to...
U.S. Healthcare Stakeholders Uncertain About Benefits of Risk Evaluation Program, According to Tufts Center for the Study of Drug Development
12 janv. 2011 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 12, 2011) - Drug developers, healthcare providers, insurance companies, and others involved in the delivery of healthcare in the United States are uncertain about...
Drug Developers Are Aggressively Changing the Way They Do R&D, According to Tufts Center for the Study of Drug Development
05 janv. 2011 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 5, 2011) - With dozens of prescription drugs due to lose their patent protection in the next few years, and few likely blockbusters in company pipelines to replace...
Personalized Medicines Are Shaping the Way R&D Is Done, According to Tufts Center for the Study of Drug Development
16 nov. 2010 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - November 16, 2010) - Personalized medicine development, occupying a growing role in the clinical pipelines of drug developers, is leading companies to change their R&D...
Pharma and Biotech Firms Are Rethinking Their Approach to Outsourcing, According to Tufts Center for the Study of Drug Development
26 oct. 2010 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - October 26, 2010) - The current business climate is challenging pharmaceutical and biotech companies to rethink their approach to outsourcing and how best to build...
Approval Success Rates Higher for Smaller Firms Among Top 50 Pharmaceutical Companies, According to Tufts Center for the Study of Drug Development
09 sept. 2010 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - September 9, 2010) - The top 10 pharmaceutical companies out of the world's top 50 have lower estimated overall clinical approval success rates than do smaller firms in that...
Portfolio Management Is Key to Improved Drug Development Productivity, According to Tufts Center for the Study of Drug Development
11 août 2010 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - August 11, 2010) - Drug developers need to change the way they allocate resources for new product development, lifecycle management, and business development and...
Comparative Effectiveness Research Could Alter Pharmaceutical Care in the United States, According to Tufts Center for the Study of Drug Development
08 juil. 2010 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 8, 2010) - Comparative effectiveness research, which assesses the relative strengths and weaknesses of various medical interventions, could help close the gap...
Rising Clinical Trial Complexity Continues to Vex Drug Developers, According to Tufts Center for the Study of Drug Development
05 mai 2010 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - May 5, 2010) - Growing clinical trial complexity continues to challenge the ability of pharmaceutical and biotechnology companies to contain the ever-rising cost of...
New Approaches to R&D May Prove Best Path for Drug Developers, According to Tufts Center for the Study of Drug Development
06 avr. 2010 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - April 6, 2010) - Innovative approaches to drug development, including alliances and partnerships, may prove the best way to increase the rate at which the...